Analysis and data insight

Biopharmaceutical collaborations: September 2019

November 22, 2019

No Comments

Biopharma licensings, joint ventures and collaborations in September 2019.

Biopharmaceutical collaborations: October 2019

November 22, 2019

No Comments

Biopharma licensings, joint ventures and collaborations in October 2019.

Biggest gainers and losers for the week of Nov. 18-22, 2019

November 22, 2019

No Comments

The top 10 biopharma stock gainers and losers for the week.

Med-tech IPO 2019 stocks up 43% led by aesthetics company Inmode

November 21, 2019

By Karen Carey

No Comments

A total of 18 med-tech companies that have gone public on U.S. exchanges this year are showing a positive percentage change in stock value on average of 43%, despite large price drops for Personalis Inc. and Guardion Health Sciences Inc.

Medtronic shines in Q2, with diabetes seeing a boost internationally

November 19, 2019

By Liz Hollis

No Comments

Medtronic plc, of Dublin, reported good news in terms of its quarterly results Tuesday, with key revenue segments coming in line with or beating expectations. Wells Fargo's Larry Biegelsen noted that coronary and structural heart sales of $955 million exceeded the consensus of $949 million and his organization's $923 million estimate. The company pointed to its transcatheter aortic valves as helping in the boost, following the expansion into the low-risk patient population.

Chinatrials 12 Summit

China looking to close gap in cell therapy market; CAR T development advancing fast

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – Although China still has a way to go to approve any CAR T therapy, clinical development is robust with various targets being studied, and the regulatory environment is improving, cell therapy experts said at the Chinatrials 12 Summit.

Spending on R&D increased during third quarter, analysis finds

November 18, 2019

No Comments

According to an analysis conducted by BioWorld of the third-quarter 2019 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) in the period increased almost 70% compared to the same period in 2018.

Money raised by biopharma: 2019 vs. 2018

November 18, 2019

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

From FDAAA to the Cures Act

FDA shifts gears on real-world evidence

November 18, 2019

By Brian Orelli

No Comments

The FDA has typically used real-world evidence (RWE) as a way of monitoring safety issues post-approval, especially through the Sentinel Initiative, which started in response to the FDA Amendments Act of 2007.